We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Merck (MRK) Q1 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Wall Street analysts forecast that Merck (MRK - Free Report) will report quarterly earnings of $2.01 per share in its upcoming release, pointing to a year-over-year increase of 43.6%. It is anticipated that revenues will amount to $15.34 billion, exhibiting an increase of 5.9% compared to the year-ago quarter.
Over the last 30 days, there has been an upward revision of 7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Merck metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Sales- Oncology- Alliance revenue- Reblozyl' at $68.77 million. The estimate indicates a change of +59.9% from the prior-year quarter.
The consensus estimate for 'Sales- Vaccines- Pneumovax' stands at $70.63 million. The estimate points to a change of -26.4% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Sales- Vaccines- ProQuar/M-M-R II/Varivax' of $544.16 million. The estimate suggests a change of +3.1% year over year.
The consensus among analysts is that 'Sales- Alliance revenue- Lenvima' will reach $265.43 million. The estimate indicates a year-over-year change of +14.4%.
Analysts predict that the 'Sales- Hospital Acute Care- Bridion - U.S.' will reach $301.76 million. The estimate indicates a change of +9.3% from the prior-year quarter.
Analysts' assessment points toward 'Product sales- Other revenues - International' reaching $198.07 million. The estimate suggests a change of -7.5% year over year.
Based on the collective assessment of analysts, 'Sales- Oncology- Keytruda - U.S.' should arrive at $4.12 billion. The estimate points to a change of +18.2% from the year-ago quarter.
The combined assessment of analysts suggests that 'Sales- Hospital Acute Care- Bridion - International' will likely reach $124.70 million. The estimate indicates a year-over-year change of -40.6%.
Analysts expect 'Sales- Animal health - International' to come in at $1.05 billion. The estimate indicates a change of +4.2% from the prior-year quarter.
According to the collective judgment of analysts, 'Sales- Animal health - U.S.' should come in at $495.47 million. The estimate indicates a year-over-year change of +2.8%.
Analysts forecast 'Sales- Vaccines- Pneumovax - International' to reach $42.22 million. The estimate points to a change of -24.6% from the year-ago quarter.
It is projected by analysts that the 'Sales- Vaccines- Pneumovax - U.S.' will reach $28.41 million. The estimate points to a change of -29% from the year-ago quarter.
Over the past month, Merck shares have recorded returns of +1.6% versus the Zacks S&P 500 composite's -4% change. Based on its Zacks Rank #3 (Hold), MRK will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exploring Analyst Estimates for Merck (MRK) Q1 Earnings, Beyond Revenue and EPS
Wall Street analysts forecast that Merck (MRK - Free Report) will report quarterly earnings of $2.01 per share in its upcoming release, pointing to a year-over-year increase of 43.6%. It is anticipated that revenues will amount to $15.34 billion, exhibiting an increase of 5.9% compared to the year-ago quarter.
Over the last 30 days, there has been an upward revision of 7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Merck metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Sales- Oncology- Alliance revenue- Reblozyl' at $68.77 million. The estimate indicates a change of +59.9% from the prior-year quarter.
The consensus estimate for 'Sales- Vaccines- Pneumovax' stands at $70.63 million. The estimate points to a change of -26.4% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Sales- Vaccines- ProQuar/M-M-R II/Varivax' of $544.16 million. The estimate suggests a change of +3.1% year over year.
The consensus among analysts is that 'Sales- Alliance revenue- Lenvima' will reach $265.43 million. The estimate indicates a year-over-year change of +14.4%.
Analysts predict that the 'Sales- Hospital Acute Care- Bridion - U.S.' will reach $301.76 million. The estimate indicates a change of +9.3% from the prior-year quarter.
Analysts' assessment points toward 'Product sales- Other revenues - International' reaching $198.07 million. The estimate suggests a change of -7.5% year over year.
Based on the collective assessment of analysts, 'Sales- Oncology- Keytruda - U.S.' should arrive at $4.12 billion. The estimate points to a change of +18.2% from the year-ago quarter.
The combined assessment of analysts suggests that 'Sales- Hospital Acute Care- Bridion - International' will likely reach $124.70 million. The estimate indicates a year-over-year change of -40.6%.
Analysts expect 'Sales- Animal health - International' to come in at $1.05 billion. The estimate indicates a change of +4.2% from the prior-year quarter.
According to the collective judgment of analysts, 'Sales- Animal health - U.S.' should come in at $495.47 million. The estimate indicates a year-over-year change of +2.8%.
Analysts forecast 'Sales- Vaccines- Pneumovax - International' to reach $42.22 million. The estimate points to a change of -24.6% from the year-ago quarter.
It is projected by analysts that the 'Sales- Vaccines- Pneumovax - U.S.' will reach $28.41 million. The estimate points to a change of -29% from the year-ago quarter.
View all Key Company Metrics for Merck here>>>
Over the past month, Merck shares have recorded returns of +1.6% versus the Zacks S&P 500 composite's -4% change. Based on its Zacks Rank #3 (Hold), MRK will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>